SAN DIEGO,
Jan. 7, 2014 /PRNewswire/ -- Mast
Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the
Company's Chief Executive Officer, Brian M.
Culley, will present at the OneMedForum Emerging Company
Finance Conference on Tuesday, January
14th, 2014 at 2:10 p.m.
Pacific time at The Westin Hotel in San Francisco.
Interested parties can access a live audio webcast and
slide presentation on the Mast Therapeutics web site at
www.masttherapeutics.com. An archived presentation will be
available on the web site for 30 days.
About Mast Therapeutics
Mast
Therapeutics, Inc. is a publicly traded biopharmaceutical company
headquartered in San Diego,
California. The Company is leveraging the
MAST (Molecular Adhesion and Sealant Technology) platform, derived
from over two decades of clinical, nonclinical and manufacturing
experience with purified and non-purified poloxamers, to develop
MST-188, its lead product candidate, for serious or
life-threatening diseases with significant unmet
needs. MST-188 is a cytoprotective,
hemorheologic, anti-inflammatory and anti-thrombotic agent that has
potential utility in diseases or conditions characterized by
microcirculatory insufficiency (endothelial dysfunction and/or
impaired blood flow).
The Company is enrolling subjects in EPIC, a pivotal phase
3 study of MST-188 in sickle cell disease. In
early 2014, the Company plans to initiate a phase 2, clinical proof
of concept study in acute limb ischemia that will evaluate whether
MST-188 improves the effectiveness of existing thrombolytic
agents. The Company also is evaluating
development options in heart failure. More
information can be found on the Company's web site at
www.masttherapeutics.com. (Twitter:
@MastThera)
Mast Therapeutics™ and the corporate logo are trademarks
of Mast Therapeutics, Inc.
Forward Looking Statements
Mast
Therapeutics cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that are based on the Company's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding the Company's
development plans for MST-188 in heart failure and acute limb
ischemia, including the timing of initiation of any clinical
studies. Among the factors that could cause or
contribute to material differences between the Company's actual
results and the expectations indicated by the forward-looking
statements are risks and uncertainties that include, but are not
limited to: delays in the commencement or completion of clinical
studies, including as a result of difficulties in obtaining
regulatory agency agreement on clinical development plans or
clinical study design, opening trial sites, enrolling study
subjects, manufacturing sufficient quantities of clinical trial
material, being subject to a "clinical hold," and/or suspension or
termination of a clinical study, including due to patient safety
concerns or lack of funding; the potential for institutional review
boards or the FDA or other regulatory agencies to require
additional nonclinical or clinical studies prior to initiation of
any planned phase 2 clinical study of MST-188; the potential that,
even if clinical studies of MST-188 in one indication are
successful, clinical studies in another indication may not be
successful; the Company's reliance on contract research
organizations (CROs), contract manufacturing organizations (CMOs),
and other third parties to assist in the conduct of important
aspects of development of MST-188, including clinical studies, and
regulatory activities for MST-188, and that such third parties may
fail to perform as expected; the potential for the Company to
delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner MST-188 at
inopportune times or pursue less expensive but higher-risk and/or
lower return development paths if it is unable to raise sufficient
additional capital as needed; and other risks and uncertainties
more fully described in the Company's press releases and periodic
filings with the Securities and Exchange Commission. The Company's
public filings with the Securities and Exchange Commission are
available at www.sec.gov.
You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date when
made. Mast Therapeutics does not intend to revise or update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date hereof,
except as may be required by law.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
SOURCE Mast Therapeutics